Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wilson, Keith E
COSI, NCT04217278: A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT	Active, not recruiting	2/3	333	Europe	Vyxeos, CPX-351, Fludarabine, Fludara, Busulphan, Busulfan, Bulsivex, Thiotepa, Tepadina, Cytarabine, Ara-C, Cytosine arabinoside	University of Birmingham, Jazz Pharmaceuticals, IMPACT (funded by NHS Blood & Transplant, Anthony Nolan and Leukaemia UK), Adienne SA	Acute Myeloid Leukaemia, High-risk Myelodysplastic Syndrome	03/25	03/25
NCT02794428: Chemoprevention of Gastric Carcinogenesis	Active, not recruiting	2	91	US, RoW	Eflornithine, Eflornithine placebo	Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.	Gastric Cancer, Gastric Intestinal Metaplasia	12/22	07/24